MaaT Pharma SA (EPA:MAAT)

Market Cap	20.01M -71.1%
Revenue (ttm)	3.18M -19.0%
Net Income	-34.31M
EPS	-1.93
Shares Out	18.84M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	55,514
Open	1.140
Previous Close	1.096
Day's Range	1.038 - 1.140
52-Week Range	0.903 - 8.620
Beta	0.62
Analysts	Buy
Price Target	6.50 (+512.05%)
Earnings Date	Sep 29, 2026

About MaaT Pharma

MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival at 12 months for patients with blood cancer receiving allogenic hematopoietic stem cell transplantation; and MaaT03X for the treatment...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 60
• Stock Exchange: Euronext Paris
• Ticker Symbol: MAAT

Financial Performance

In 2025, MaaT Pharma's revenue was 4.52 million, an increase of 40.67% compared to the previous year's 3.22 million. Losses were -31.06 million, 7.46% more than in 2024.

Analyst Summary

According to 2 analysts, the average rating for MAAT stock is "Buy." The 12-month stock price target is €6.50, which is an increase of 512.05% from the latest price.

Price Target

€6.50

(512.05% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 22, 2026

Data Sources Report a data error